中文 
别名:Nuclear receptor coactivator 3 (NCoA-3) (EC 2.3.1.48) (ACTR) (Amplified in breast cancer 1 protein) (AIB-1) (CBP-interacting protein) (pCIP) (Class E basic helix-loop-helix protein 42) (bHLHe42) (Receptor-associated coactivator 3) (RAC-3) (Steroid receptor coactivator protein 3) (SRC-3) (Thyroid hormone receptor activator molecule 1) (TRAM-1)应用:WB
反应种属:Human
规格：50μl/100μl
| Description |
|---|
| nuclear receptor coactivator 3(NCOA3) Homo sapiens The protein encoded by this gene is a nuclear receptor coactivator that interacts with nuclear hormone receptors to enhance their transcriptional activator functions. The encoded protein has histone acetyltransferase activity and recruits p300/CBP-associated factor and CREB binding protein as part of a multisubunit coactivation complex. This protein is initially found in the cytoplasm but is translocated into the nucleus upon phosphorylation. Several transcript variants encoding different isoforms have been found for this gene. In addition, a polymorphic repeat region is found in the C-terminus of the encoded protein. [provided by RefSeq, Mar 2010], |
| Specification | |
|---|---|
| Aliases | Nuclear receptor coactivator 3 (NCoA-3) (EC 2.3.1.48) (ACTR) (Amplified in breast cancer 1 protein) (AIB-1) (CBP-interacting protein) (pCIP) (Class E basic helix-loop-helix protein 42) (bHLHe42) (Receptor-associated coactivator 3) (RAC-3) (Steroid receptor coactivator protein 3) (SRC-3) (Thyroid hormone receptor activator molecule 1) (TRAM-1) |
| Entrez GeneID | 8202 |
| Swissprot | Q9Y6Q9 |
| WB Predicted band size | 160kDa |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized phosho peptide around human SRC-3 (Thr24) |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Application | |
|---|---|
| WB | 1/1000-2000 |
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的，不可用于人类或动物的临床诊断或治疗，非药用，非食用。
暂无评论
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的，不可用于人类或动物的临床诊断或治疗，非药用，非食用。
发表回复